In questo studio si dimostravano i vantaggi del Ticagrelor sul Clopidogrel in termini di mortalità, tanto da suscitare l’entusiasmo del presidente dell’ American College of Cardiology, Doug Weaver (Henry Ford Health System, Detroit, MI), che dichiarava: “I think it’s the best result we’ve seen since aspirin, which was the last time we saw an antiplatelet drug with a mortality benefit. It could not have come out better. I really do think it’s going to surpass clopidogrel and pass prasugrel–it looks safer than prasugrel. In my own personal opinion, clopidogrel is too expensive for what you get. This is much, much better.”